Coia Dulsat

Barcelona

Staff Writer at BioWorld

Staff Writer at BioWorld Science

Featured in: Favicon

bioworld.com

Articles

Loss of Y chromosome in cancer, immune cells: a new clue to cancer outcomes

1 day ago | bioworld.com | Coia Dulsat

Researchers from the University of Arizona have unveiled that coordinated Y chromosome loss in both cancer cells and immune cells may explain the worse prognosis in people with this alteration. The loss of the Y chromosome (LOY) is one of the most frequent somatic mutations in men, particularly with advancing age. More specifically, LOY shows increasing prevalence in circulating blood cells, affecting around 2.5% of 40-year-old men and up to 40% of 70-year-old men.
Loss of Y chromosome in cancer, immune cells: a new clue to cancer outcomes

2 days ago | bioworld.com | Coia Dulsat

CancerLoss of Y chromosome in cancer, immune cells: a new clue to cancer outcomesResearchers from the University of Arizona have unveiled that coordinated Y chromosome loss in both cancer cells and immune cells may explain the worse prognosis in people with this alteration. The loss of the Y chromosome (LOY) is one of the most frequent somatic mutations in men, particularly with advancing age.
Loss of Y chromosome in cancer, immune cells: a new clue to cancer outcomes

3 days ago | bioworld.com | Coia Dulsat

CancerLoss of Y chromosome in cancer, immune cells: a new clue to cancer outcomesResearchers from the University of Arizona have unveiled that coordinated Y chromosome loss in both cancer cells and immune cells may explain the worse prognosis in people with this alteration. The loss of the Y chromosome is one of the most frequent somatic mutations in men, particularly with advancing age. BioWorld MedTech Cancer
Modified viral protein boosts T cell power via STAT5

1 week ago | bioworld.com | Coia Dulsat

CancerModified viral protein boosts T cell power via STAT5Researchers at the University of Michigan designed an optimized viral protein able to boost the antitumor function of T cells. The project stemmed from observations on the particular system employed by Herpesvirus saimiri to infect T cells and hijack cellular pathways by activating them. BioWorld Science Cancer
Amphiregulin drives metastasis through a paradoxical ‘badscopal’ effect of radiotherapy

2 weeks ago | bioworld.com | Coia Dulsat

CancerAmphiregulin drives metastasis through a paradoxical ‘badscopal’ effect of radiotherapyResearchers at the University of Chicago have shed light on the role of tumor-promoting factors induced by radiotherapy and their potential impact on future therapeutic strategies. The article, published in Nature on May 14, 2025, points to radiation-induced amphiregulin as a key driver of tumor metastasis. BioWorld Science Cancer
Lipid uptake drives immune evasion in high-grade serous ovarian cancer

3 weeks ago | bioworld.com | Coia Dulsat

Home » Lipid uptake drives immune evasion in high-grade serous ovarian cancer BioWorld briefs for May 12, 2025. BioWorld MedTech briefs for May 12, 2025. After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,... Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategyâ€™s ultimate clinical...
ADPD 2025: Novel treatment modalities in neurodegenerative disorders

1 month ago | bioworld.com | Coia Dulsat

ADPD 2025: Novel treatment modalities in neurodegenerative disordersThe current treatment strategies for neurodegenerative diseases focus on targeting Aβ in Alzheimer’s disease (AD), α-synuclein aggregates in Parkinson’s disease (PD) and anti-tau therapies, which are primarily used in AD but are also being explored for PD.
ADPD 2025: Novel treatment modalities in neurodegenerative disorders

1 month ago | bioworld.com | Coia Dulsat

Neurology/psychiatricADPD 2025: Novel treatment modalities in neurodegenerative disordersThe current treatment strategies for neurodegenerative diseases focus on targeting Aβ in Alzheimer’s disease (AD), α-synuclein aggregates in Parkinson’s disease (PD) and anti-tau therapies, which are primarily used in AD but are also being explored for PD.
ADPD 2025: Unfolding the field of neurolipidomics

2 months ago | bioworld.com | Coia Dulsat

Home » ADPD 2025: Unfolding the field of neurolipidomics BioWorld briefs for April 4, 2025. BioWorld MedTech briefs for April 4, 2025. At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald... At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk A/S, who has extensive experience in...
ADPD 2025: Unfolding the field of neurolipidomics

2 months ago | bioworld.com | Coia Dulsat

Home » ADPD 2025: Unfolding the field of neurolipidomics BioWorld briefs for April 4, 2025. BioWorld MedTech briefs for April 4, 2025. At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald... Although the causes of polycystic ovary syndrome (PCOS) are unclear, researchers know this condition leads to endometrial dysfunction in women who have hormonal...